Minerva Neurosciences | NERV - Des Atouts

Prix De L'Action
6.96
Variation Quotidienne
-0.59 -7.76%
Mensuellement
11.28%
Annuel
275.95%
Q1 Prévisions
7.31




Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Adma Biologics USD 624.24M 55.56M 2025-12
ALKERMES USD 2.49B 157.48M 2025-12
Alterity Therapeutics Limited AUD 27.32M 6.07M 2023-06
AstraZeneca USD 114.07B 382M 2025-12
BioCryst Pharmaceuticals USD 514.16M 67.73M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Cipla INR 401.64B 27.77B 2025-09
Clal Biotechnology ILS 158.39M 24.3M 2023-12
Compugen USD 156.57M 58.73M 2025-12
CSL USD 37.9B 1.5B 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
Esperion Therapeutics USD 465.89M 101.87M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
Grifols EUR 23.15B 142.7M 2025-12
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
J&J USD 199.21B 6.39B 2025-12
Merck USD 129.55B 12.02B 2025-09
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Novartis USD 110.95B 3.66B 2025-12
Novavax USD 1.18B 3.38M 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Roche Holding CHF 100.7B 5.94B 2025-12
Sanofi EUR 126.81B 2.99B 2025-12
Takeda JPY 15.41T 938.47B 2025-12
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12